Skip to content
The BCI Briefing

Company profileCore BCI

Blackrock Neurotech

Maker of the electrode arrays behind most human intracortical BCI research.

Location
Salt Lake City, United States
Founded
2008
Sources last checked
6 Oct 2026

What they are building

Supplies Utah-array-based recording and stimulation systems used in long-running academic studies, and develops its own clinical BCI products.

Signal
Intracortical: Action potentials and local field potentialsIntracortical + ICMS: Spikes out; microamp pulses in
Invasiveness
Invasive
Recording / stimulation
Recording and stimulation
Device
Utah array (NeuroPort) — Rigid silicon microelectrode array, typically connected through a skull-mounted pedestal
Channels
96 electrodes per array in most human studies
Regulatory status
Investigational for chronic BCI use
Main use cases
Control, Communicate, Move, Feel
Works with
University of Pittsburgh · Johns Hopkins University

Where they are clinically

Feasibility

Small early studies that test safety and whether the device can do what it is meant to.

Access today

Clinical study

Accessible only by enrolling in a registered clinical study.

Shown in people
Its arrays recorded most of the field's peer-reviewed human results, among them speech at 97.5% word accuracy and touch feedback that cut a grasping task from 20.9 to 10.2 seconds.
Still an aim
A product of its own that a clinician can prescribe. None is authorised.
What stands in the way
Form: a rigid 96-electrode array, wired through the skull in most studies, against fully implanted wireless designs.

On record here: 3 registered studies · 62 participants planned or enrolled · 5 peer-reviewed papers

This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.

Why this company matters

Nearly every landmark academic result in speech, handwriting and sensory feedback was recorded through Utah-style arrays, which gives Blackrock the longest human track record in the field. Its challenge is converting a research-instrument business into a product a clinician can prescribe, against newer fully implanted, wireless designs.

Key milestones

  1. Sep 2026

    Named as collaborator on a Johns Hopkins study of higher-throughput intracortical interfaces.

    Interfacing with neurotechnology to expand neural throughput · NCT07521930

  2. 29 Apr 2024

    Tether invests $200M and becomes the majority shareholder.

    The Block

Clinical programmes

  • Interfacing with neurotechnology to expand neural throughput

    Academic study with Blackrock Neurotech as collaborator.

    FeasibilityRecruiting

    5 estimatedNCT07521930

  • CRS-BMI

    Bidirectional intracortical BCI: motor decoding with tactile feedback by microstimulation.

    FeasibilityRecruiting

    30 estimatedNCT01894802

  • BrainGate2

    The longest-running intracortical BCI study, open since 2009 across six US sites.

    FeasibilityRecruiting

    27 estimatedNCT00912041

Research

Funding history

  • 29 Apr 2024$200MStrategic investment · led by TetherTether became the majority shareholder, so this is a change of control as much as a financing.

Investors namedTether

Rounds in the Briefing’s sample only; not a complete funding history.

IP and patents

Filings touch 4 of the 11 layers, most often interface and electrodes (11 of 14 families) and stimulation (11).

14
patent families identified and counted as BCI
2009
earliest first filing among them
9
first filed since 2021; the latest years are incomplete
3 of 14
include a granted member, of those whose family record was read

Across the stack: families by layer

Themes, by number of families: stimulation (11), electrodes and arrays (10), wireless telemetry (4), signal acquisition (2), connectors and feedthroughs (2), wireless power (2). A family can carry several.

Published in: United States (12), Australia (2), China (1), counted over the 14 families whose full record was read.

8 more families counted

Families found for Blackrock Neurotech in the EPO’s worldwide database, grouped so that one invention counts once. A filing shows what a company sought to protect. It does not show that the technology was built, is in a product, or works in people, and themes are read from titles, abstracts and classes, not from the claims. How to read this

Competitive context

Sources

  1. 01

    Tether invests $200 million in biotech firm Blackrock Neurotech (opens in a new tab)

    Independent reportingThe Block29 Apr 2024Checked against source 6 Oct 2026

    Reports that Tether became the majority shareholder.

  2. 02

    ClinicalTrials.gov NCT07521930 (opens in a new tab)

    Clinical registryClinicalTrials.gov2 Sep 2026Checked against source 3 Oct 2026

    Registry record last updated 2026-09-02.